CMBA
ENTA icon

C.M. Bidwell & Associates’s Enanta Pharmaceuticals ENTA Stock Holding History

C.M. Bidwell & Associates’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.83K Hold
331
– – ﹤0.01% 347
2026
Q1 		$4.18K Buy
+331
New +$4.44K ﹤0.01% 345
2022
Q1 		– Sell
-1,143
Closed -$85K – 557
2021
Q4 		$85K Buy
+1,143
New +$89.7K 0.05% 249

Other funds holding ENTA

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KAM
Krensavage Asset Management New York $263M AUM 66.99% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SSC
Spruce Street Capital New York $510M AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

C.M. Bidwell & Associates's ENTA Position: Q2 2026 in Review

C.M. Bidwell & Associates held its Enanta Pharmaceuticals (ENTA) position steady in Q2 2026 at 331 shares worth $4.83K. The position accounts for ﹤0.01% of the portfolio, ranked #347.

C.M. Bidwell & Associates first reported a position in ENTA in Q4 2021 and has held it in 3 quarters since. The position peaked at $85K in Q4 2021. 123 funds tracked by Wall St. Rank hold ENTA as of Q2 2026.

  • C.M. Bidwell & Associates held 331 shares of Enanta Pharmaceuticals worth $4.83K as of Q2 2026.
  • C.M. Bidwell & Associates left its Enanta Pharmaceuticals share count unchanged in Q2 2026.
  • Enanta Pharmaceuticals made up ﹤0.01% of C.M. Bidwell & Associates's portfolio in Q2 2026, its #347 holding.
  • C.M. Bidwell & Associates first reported a position in Enanta Pharmaceuticals in Q4 2021 and has held it in 3 quarters since.
  • C.M. Bidwell & Associates's Enanta Pharmaceuticals position peaked at $85K in Q4 2021.
  • 123 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2026.

Based on C.M. Bidwell & Associates's 13F filing for Q2 2026, filed 11 Aug 2026.